Kiessling MK - Search Results

1

Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma.

Kiessling MK, Klemke CD, Kaminski MM, Galani IE, Krammer PH, Gülow K. Kiessling MK, et al. Cancer Res. 2009 Mar 15;69(6):2365-74. doi: 10.1158/0008-5472.CAN-08-3221. Epub 2009 Mar 3. Cancer Res. 2009. PMID: 19258503

2

Inhibition of NF-κB induces a switch from CD95L-dependent to CD95L-independent and JNK-mediated apoptosis in T cells.

Kiessling MK, Linke B, Brechmann M, Süss D, Krammer PH, Gülow K. Kiessling MK, et al. FEBS Lett. 2010 Nov 19;584(22):4679-88. doi: 10.1016/j.febslet.2010.10.047. Epub 2010 Oct 26. FEBS Lett. 2010. PMID: 20974135 Free article.

3

Novel role for mitochondria: protein kinase Ctheta-dependent oxidative signaling organelles in activation-induced T-cell death.

Kaminski M, Kiessling M, Süss D, Krammer PH, Gülow K. Kaminski M, et al. Mol Cell Biol. 2007 May;27(10):3625-39. doi: 10.1128/MCB.02295-06. Epub 2007 Mar 5. Mol Cell Biol. 2007. PMID: 17339328 Free PMC article.

4

No life without death.

Krammer PH, Kamiński M, Kiessling M, Gülow K. Krammer PH, et al. Adv Cancer Res. 2007;97:111-38. doi: 10.1016/S0065-230X(06)97005-5. Adv Cancer Res. 2007. PMID: 17419943 Review.

5

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

Kiessling MK, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM, Girardi M, Macconaill LE, Kehoe SM, Hatton C, French LE, Garraway LA, Polier G, Süss D, Klemke CD, Krammer PH, Gülow K, Dummer R. Kiessling MK, et al. Blood. 2011 Feb 24;117(8):2433-40. doi: 10.1182/blood-2010-09-305128. Epub 2011 Jan 5. Blood. 2011. PMID: 21209378 Free PMC article.

6

NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.

Kießling MK, Nicolay JP, Schlör T, Klemke CD, Süss D, Krammer PH, Gülow K. Kießling MK, et al. Oncotarget. 2017 Jul 11;8(28):45687-45697. doi: 10.18632/oncotarget.17669. Oncotarget. 2017. PMID: 28537899 Free PMC article.

7

A PP4 holoenzyme balances physiological and oncogenic nuclear factor-kappa B signaling in T lymphocytes.

Brechmann M, Mock T, Nickles D, Kiessling M, Weit N, Breuer R, Müller W, Wabnitz G, Frey F, Nicolay JP, Booken N, Samstag Y, Klemke CD, Herling M, Boutros M, Krammer PH, Arnold R. Brechmann M, et al. Immunity. 2012 Oct 19;37(4):697-708. doi: 10.1016/j.immuni.2012.07.014. Immunity. 2012. PMID: 23084358 Free article.

8

Mutant HRAS as novel target for MEK and mTOR inhibitors.

Kiessling MK, Curioni-Fontecedro A, Samaras P, Atrott K, Cosin-Roger J, Lang S, Scharl M, Rogler G. Kiessling MK, et al. Oncotarget. 2015 Dec 8;6(39):42183-96. doi: 10.18632/oncotarget.5619. Oncotarget. 2015. PMID: 26544513 Free PMC article.

9

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening.

Kiessling MK, Schuierer S, Stertz S, Beibel M, Bergling S, Knehr J, Carbone W, de Vallière C, Tchinda J, Bouwmeester T, Seuwen K, Rogler G, Roma G. Kiessling MK, et al. BMC Genomics. 2016 Sep 9;17(1):723. doi: 10.1186/s12864-016-3042-2. BMC Genomics. 2016. PMID: 27613601 Free PMC article.

10

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.

Kiessling MK, Curioni-Fontecedro A, Samaras P, Lang S, Scharl M, Aguzzi A, Oldrige DA, Maris JM, Rogler G. Kiessling MK, et al. PLoS One. 2016 Jan 28;11(1):e0147682. doi: 10.1371/journal.pone.0147682. eCollection 2016. PLoS One. 2016. PMID: 26821351 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page